Navigation Links
PRT054021 in Medical Technology

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

...ulants, determined that EXPERT met its objectives: prt054021 appeared effective and safe at the two doses studi... look forward to studying the unique properties of prt054021 in additional clinical trials." About prt054021 - Portola's Factor Xa Inhibitor ...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

...tled "Evaluation of the Factor Xa (FXA) Inhibitor, prt054021 (PRT021), against Enoxaparin in Randomized Trial f...0 p.m. (CEST) in the exhibition area. About prt054021 -- Portola's Factor Xa Inhibitor prt054021 is an oral Factor Xa inhibitor, an anticoagulant i...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

...replacement (TKR) surgery. Portola expects to move prt054021 into Phase III clinical development in VTE prevent... compare the safety and antithrombotic activity of prt054021 with that of enoxaparin. A steering committee of l... concluded that EXPERT met its objectives and that prt054021 was safe and effective at the doses studied. ...
PRT054021 in other areas

Healthcare Sales & Marketing Network News: Portola Pharmaceuticals ...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery (HSMN ...

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention ...

Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for ... Drug: PRT054021. Phase II. Study Type: Interventional. Study Design: ...

医药工业研究院_新闻中心

Based on these results, Portola will advance PRT054021 into further clinical testing. ... PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being ...

Phase II Study Of Factor Xa Inhibitor Gives Positive Results, Drug ...

... announced positive Phase II data on its lead compound, PRT054021, an oral Factor Xa inhibitor. ... expects to move PRT054021 into Phase III clinical ...

Portola Announces Positive Data on Factor Xa Inhibitor in VTE Trial

Portola Pharmaceuticals has received positive results from EXPERT, a Phase II study of its oral Factor Xa inhibitor, PRT054021, for the prevention of venous ...

Portola Pharmaceuticals, Inc. Announces Positive Phase II EXPERT ...

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being ... In addition, PRT054021 is not excreted in the kidneys and therefore will not ...
Other Tags
(Date:12/19/2014)... (HealthDay News) -- A new study suggests a possible ... hot flashes and night sweats -- and higher rates ... are common during menopause, affecting about 60 percent of ... after menopause, since they then face a higher risk ... women who exhibit moderate or severe menopausal symptoms are ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... December 17, 2014 Dr. Myo Nwe is ... Loss Diet of the Future” and co-founder of the Ace ... book, Dr. Nwe takes a broad look at the industry ... up under scientific scrutiny. On film and in television shows, ... mostly toward the social aspects and played for basic laughs, ...
(Date:12/17/2014)... San Francisco, CA (PRWEB) December 17, 2014 ... the Stanford Center for Longevity, today, in reaction to a ... the emerging science of brain training and derogated the efficacy ... said that they agreed with the parts of the center’s ... however, they believed the center had also overstated its case, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview of ... and Obamacare architect Jonathan Gruber to public attention. Award-winning ... which is being distributed on YouTube. , During the ... the Affordable Care Act in order to hide a ... per year tax grab. , “President Obama promised us ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
Other Contents